Compare FHB & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FHB | AMLX |
|---|---|---|
| Founded | 1858 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.8B |
| IPO Year | 2016 | 2021 |
| Metric | FHB | AMLX |
|---|---|---|
| Price | $26.14 | $28.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 12 |
| Target Price | $29.11 | ★ $43.00 |
| AVG Volume (30 Days) | ★ 1.8M | 1.2M |
| Earning Date | 10-23-2026 | 11-05-2026 |
| Dividend Yield | ★ 4.11% | N/A |
| EPS Growth | 22.91 | ★ 65.46 |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $880,788,000.00 | $380,786,000.00 |
| Revenue This Year | $7.56 | N/A |
| Revenue Next Year | $53.05 | N/A |
| P/E Ratio | $22.07 | ★ N/A |
| Revenue Growth | 8.94 | ★ 1612.94 |
| 52 Week Low | $23.26 | $10.83 |
| 52 Week High | $30.58 | $41.14 |
| Indicator | FHB | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 62.92 | 50.90 |
| Support Level | $25.20 | $12.97 |
| Resistance Level | $26.18 | $34.35 |
| Average True Range (ATR) | 0.44 | 1.28 |
| MACD | 0.18 | 0.22 |
| Stochastic Oscillator | 99.26 | 73.48 |
First Hawaiian Inc is a bank holding company. It provides a diversified range of banking services to consumer and commercial customers, including deposit products, lending services, and wealth management and trust services. The company offers a variety of deposit products to its customers, including checking and savings accounts and other types of deposit accounts. It provides commercial and industrial lending, including auto dealer flooring, commercial real estate, and construction lending. It also offers comprehensive consumer lending services focused on residential real estate lending, indirect auto financing, and other consumer loans. The company's segments are Retail Banking, Commercial Banking, and Treasury, and others of which key revenue is derived from Retail Banking.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.